ArticleAntimicrobial agents and chemotherapy2024
Liposomal formulation of a new antifungal hybrid compound provides protection against
Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Methods for skin load reduction of Candida auris: a systematic review.Antimicrobial resistance and infection control · 2026Pooled it
- Review
- Methylene Blue-Loaded Liposomal Nanocarriers Enhance the Efficacy of Photodynamic Therapy againstACS infectious diseases · 2026Article
- Large-scale virtual screening of 17,967 IMPPAT phytochemicals identifies multiple CDR1 binders and reveals Apigenin-7-O-glucuronide as a putative CDR1-GSC1 dual-target lead againstFrontiers in cellular and infection microbiology · 2026Article
- Bridging bioactive metabolites ofFrontiers in pharmacology · 2026Review
- StudyingPharmaceuticals (Basel, Switzerland) · 2025Review
- Nanomaterials for Photocatalytic Inactivation and Eradication ofMolecules (Basel, Switzerland) · 2025Review
- Indazole - an emerging privileged scaffold: synthesis and its biological significance.RSC medicinal chemistry · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Resilience in Resistance: The Role of Cell Wall Integrity in Multidrug-Resistant Candida.Journal of fungi (Basel, Switzerland) · 2025Review
- Insights into Liposomal and Gel-Based Formulations for Dermatological Treatments.Gels (Basel, Switzerland) · 2025Review
- Unveiling the mechanisms of synthetic compounds againstCurrent research in pharmacology and drug discovery · 2025Review
- The multidrug-resistantCurrent research in microbial sciences · 2025Review
- New Ground in Antifungal Discovery and Therapy for Invasive Fungal Infections: Innovations, Challenges, and Future Directions.Journal of fungi (Basel, Switzerland) · 2024Review
- Current Perspectives of Antifungal Therapy: A Special Focus onJournal of fungi (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 5 countries.
Funding
Abstract
The newly emerged pathogen,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.